Opinions

Despite generally disappointing clinical trial results, technological innovations mean that realising the potential for cancer vaccines could be just around the corner

While some challenges associated with rare cancers are similar in Europe and Asia, resources and differing epidemiology need to be considered when coming up with solutions 

Results from a pilot study show that work–family balance is the biggest challenge to career progression for young women 

A new level of sophistication, namely genome editing, is now available to help overcome previous hurdles with adoptive T-cell therapies

The identification of mutation-derived neoantigens may help elicit antitumour immune responses in patients with cancer, but this approach is challenging 

Side-effects may occur at unpredictable timepoints during a patient’s treatment journey and even after treatment cessation  

Recent evidence shows the potential of immunotherapy to change the treatment landscape of triple-negative breast cancer (TNBC), where historically, chemotherapy has been the only systemic option. But, how do we choose what therapy to give which patients?

After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups

The availability and affordability of a broad range of prescription cancer medicines have been analysed

In the post-COVID-19 era, there is a need to evaluate the quality, safety and effectiveness of telehealth to deliver cancer care says ESMO Keynote Lecturer Dr Deborah Schrag